Stilton campaigners meet ‘big cheeses’ in name row

Thanks to Westminster and the E.U., Stilton from Stilton can’t be Stilton.

Campaigners who want blue cheese made in the Cambridgeshire village of Stilton to be officially called Stilton are taking their fight to Westminster.

Resident Richard Landy is seeking to overturn a Defra decision refusing to recognise the cheese as Stilton.

Under EU law, Stilton can only be produced in Leicestershire, Derbyshire and Nottinghamshire, where it is thought the cheese originated.

[…]

“We just want the right to produce the cheese in Stilton. It’s the only protected food name product in the whole of Europe that can’t be produced in the place it’s named after.”

Mr Vara said: “I believe that the historic village of Stilton should be able to manufacture the world famous cheese of its namesake in the village itself.

Fricking bureaucrats and Eurocrats…

Advertisements

FDA Rules No Wooden Boards in Cheese Aging

Tyrannical!

A sense of disbelief and distress is quickly rippling through the U.S. artisan cheese community, as the federal Food and Drug Administration (FDA) this week announced it will not permit American cheesemakers to age cheese on wooden boards.

Recently, the FDA inspected several New York state cheesemakers and cited them for using wooden surfaces to age their cheeses. The New York State Department of Agriculture & Markets’ Division of Milk Control and Dairy Services, which (like most every state in the U.S., including Wisconsin), has allowed this practice, reached out to FDA for clarification on the issue. A response was provided by Monica Metz, Branch Chief of FDA’s Center for Food Safety and Applied Nutrition’s (CFSAN) Dairy and Egg Branch.

In the response, Metz stated that the use of wood for cheese ripening or aging is considered an unsanitary practice by FDA, and a violation of FDA’s current Current Good Manufacturing Practice (cGMP) regulations.

[…]

The most interesting part of the FDA’s statement it that it does not consider this to be a new policy, but rather an enforcement of an existing policy. And worse yet, FDA has reiterated that it does not intend to change this policy.